Enliven Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -14 | -46 | -81 | |
EBITDA | -23,613 | -29,621 | -20,086 | -25,254 |
EBIT | -23,627 | -29,667 | -20,148 | -25,335 |
Net Income | -23,627 | -29,667 | -20,148 | -25,335 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -19,291 | -15,838 | -13,278 | -17,196 |
Cash | 132,184 | 98,896 | 101,732 | 119,437 |
Basic Shares | 62,799 | 56,664 | 62,093 | 52,105 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -263 | -317 | -297 | -622 |
EBITDA | -103,431 | -88,475 | -71,287 | -37,447 |
EBIT | -103,694 | -88,792 | -71,584 | -37,662 |
Net Income | -103,694 | -89,024 | -71,584 | -37,662 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -70,459 | -73,236 | -61,418 | -32,689 |
Cash | 98,896 | 124,117 | 100,141 | 75,536 |
Basic Shares | 56,664 | 47,073 | 35,546 | 6,249 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.38 |
2025-12-31 | -$0.48 |
2025-09-30 | -$0.32 |
2025-06-30 | -$0.49 |